TNFSF4 and neoplasm: Based on our findings, it could be hypothesized that OX40L+ G-BMDCs, when used for DC-based vaccination, may suppress anti-tumor effector immune responses through the expansion of Tregs, and therefore, lead to suboptimal immune response and/or treatment failure.